LR Health & Beauty released its Q4 2025 financial results and preliminary full-year 2025 figures, reporting year-over-year revenue declines and reduced EBITDA, largely attributed to softer consumer sentiment in Western Europe and exceptional items tied to financing restructuring.
Shares and stakeholders are closely watching the company’s operational turnaround strategy as it prepares to launch a new product generation in spring 2026.
Reported in USD (Converted Figures)
Official Report (EUR-Based Reporting)
LR reports under EUR in its consolidated financial statement:
The direction of the results is consistent across both currencies: revenue declined approximately 11% year over year, and EBITDA contracted significantly in Q4.
Converted Figures (USD)
Official EUR Figures
The decline reflects a challenging consumer environment, particularly in Western Europe, along with financial restructuring costs.
The apparent mismatch between reported figures comes from:
The overall performance narrative remains consistent: mid-single-digit annual sales decline and a sharp EBITDA drop in Q4.
A key contextual factor behind the results is LR’s financing structure realignment, which includes:
These restructuring measures aim to strengthen the balance sheet and create long-term stability, even though short-term earnings were affected.
LR signaled plans to launch a new generation product portfolio in spring 2026, combining health and beauty categories.
This initiative appears positioned to:
New product cycles often play a significant role in direct selling momentum, particularly in mature European markets.
CEO Jörg Körfer emphasized progress in restructuring efforts and expressed confidence in upcoming growth initiatives tied to product innovation and financial stabilization.
âś” Q4 revenue declined approximately 11% year over year
âś” Full-year sales down mid-single digits
âś” EBITDA sharply lower in Q4
âś” Financing restructuring impacted short-term profitability
âś” Spring 2026 product launch may act as a growth catalyst
LR Health & Beauty’s 2025 results reflect a company navigating:
While revenue contraction and EBITDA pressure raise short-term concerns, the company’s capital realignment and planned product refresh suggest an effort to reset growth momentum heading into 2026.
The key factors to watch next include:
Get more information
There are no reviews yet. Be the first one to write one.
